JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

224.91 -2.38

Buy Sell

Overview

Share price change

24h

Current

Min

223.86

Max

230.62

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+28.38% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.5B 15B
Previous open	227.29
Previous close	224.91

News Sentiment

By Acuity

50%

179 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 kwi 2026, 00:00 UTC

Major News Events

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 kwi 2026, 23:33 UTC

Earnings

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 kwi 2026, 22:40 UTC

Earnings

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:11 UTC

Earnings

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 kwi 2026, 21:01 UTC

Earnings

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 kwi 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 kwi 2026, 23:34 UTC

Market Talk

Major News Events

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 kwi 2026, 23:16 UTC

Earnings

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 kwi 2026, 23:15 UTC

Earnings

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 kwi 2026, 22:52 UTC

Earnings

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 kwi 2026, 22:51 UTC

Earnings

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 kwi 2026, 22:30 UTC

Earnings

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 kwi 2026, 22:30 UTC

Earnings

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 kwi 2026, 22:29 UTC

Earnings

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 kwi 2026, 22:27 UTC

Earnings

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 kwi 2026, 22:06 UTC

Market Talk

Earnings

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:47 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:37 UTC

Earnings

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 kwi 2026, 21:34 UTC

Earnings

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 kwi 2026, 21:29 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:20 UTC

Market Talk

Earnings

Tesla Expands Manufacturing to Chips -- Market Talk

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

28.38% upside

12 Months Forecast

Average 296.62 USD 28.38%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

179 / 348 Ranking in Healthcare

Financials

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.